Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

被引：12

作者：

Gilabert, Marine ^{[1
,2
]}

Raoul, Jean-Luc ^{[3
]}

机构：

[1] Paoli Calmettes Inst, Dept Med Oncol, 232 Bd St Marguerite, F-13232 Marseille 9, France

[2] Aix Marseille Univ, Inst Natl Sante & Rech Med 1068, Stress Cell Unit, Ctr Rech Cancerol Marseille, Marseille 8, France

[3] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, F-44805 Nantes, France

来源：

JOURNAL OF HEPATOCELLULAR CARCINOMA | 2018年 / 5卷

关键词：

hepatocellular carcinoma; antiangiogenic drugs; ramucirumab; RANDOMIZED PHASE-III; DOUBLE-BLIND; 1ST-LINE TREATMENT; OPEN-LABEL; SORAFENIB; PLACEBO; CHEMOTHERAPY; MULTICENTER; COMBINATION; THERAPY;

D O I：

10.2147/JHC.S157413

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) represents similar to 90% of primary liver cancers and constitutes a major global health problem. Since a decade ago, the management of advanced disease that cannot be locally treated has mainly been based on multi-targeted antiangiogenic therapies. Some have demonstrated improvement in overall survival over best supportive care in first-and second-line treatment. This study focused on the efficacy of antiangiogenics in patients with advanced HCC and particularly the rising role of ramucirumab in patients with elevated alpha-fetoprotein at diagnosis.

引用

页码：91 / 98

页数：8

共 54 条

[41] Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade [J].

Rigamonti, Nicolo ;

Kadioglu, Ece ;

Keklikoglou, Ioanna ;

Rmili, Celine Wyser ;

Leow, Ching Ching ;

De Palma, Michele .

CELL REPORTS, 2014, 8 (03) :696-706

[42] The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway [J].

Roodhart, Jeanine M. ;

Langenberg, Marlies H. ;

Witteveen, Els ;

Voest, Emile E. .

CURRENT CLINICAL PHARMACOLOGY, 2008, 3 (02) :132-143

[43] The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients [J].

Sangiovanni, Angelo ;

Prati, Gian Maria ;

Fasani, Pierangelo ;

Ronchi, Guido ;

Romeo, Raffaella ;

Manini, Matteo ;

Del Ninno, Ersiho ;

Morabito, Alberto ;

Colombo, Massimo .

HEPATOLOGY, 2006, 43 (06) :1303-1310

[44] Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma [J].

Siegel, Abby B. ;

Cohen, Emil I. ;

Ocean, Allyson ;

Lehrer, Deborah ;

Goldenberg, Alec ;

Knox, Jennifer J. ;

Chen, Helen ;

Clark-Garvey, Sean ;

Weinberg, Alan ;

Mandeli, John ;

Christos, Paul ;

Mazumdar, Madhu ;

Popa, Elizabeta ;

Brown, Robert S., Jr. ;

Rafii, Shahin ;

Schwartz, Jonathan D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) :2992-2998

[45] Cancer Statistics, 2014 [J].

Siegel, Rebecca ;

Ma, Jiemin ;

Zou, Zhaohui ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (01) :9-29

[46] Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 [J].

Spratlin, Jennifer L. ;

Cohen, Roger B. ;

Eadens, Matthew ;

Gore, Lia ;

Camidge, D. Ross ;

Diab, Sami ;

Leong, Stephen ;

O'Bryant, Cindy ;

Chow, Laura Q. M. ;

Serkova, Natalie J. ;

Meropol, Neal J. ;

Lewis, Nancy L. ;

Chiorean, E. Gabriela ;

Fox, Floyd ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (05) :780-787

[47] Medical treatments for hepatocellular carcinoma (HCC): what's next? [J].

Taieb, J. ;

Barbare, J. C. ;

Rougier, P. .

ANNALS OF ONCOLOGY, 2006, 17 :X308-X314

[48] A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma [J].

Thomas, Melanie B. ;

Garrett-Mayer, Elizabeth ;

Anis, Munazza ;

Anderton, Kate ;

Bentz, Tricia ;

Edwards, Andie ;

Brisendine, Alan ;

Weiss, Geoffrey ;

Siegel, Abby B. ;

Bendell, Johanna ;

Baron, Ari ;

Duddalwar, Vinay ;

El-Khoueiry, Anthony .

ONCOLOGY, 2018, 94 (06) :329-339

[49] Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

[50]

Yao Deng-Fu, 2005, Hepatobiliary Pancreat Dis Int, V4, P220

← 1 2 3 4 5 6 →